12.18

7.31% +0.83

KalVista Pharmaceuticals Inc (KALV)

Overview News Price History Option Chain Discussions Forecast Stock Split

KalVista Pharmaceuticals Inc stock is currently priced at $12.18, with a 24-hour trading volume of 481.49K. It has seen a +7.31% increased in the last 24 hours and a +6.84% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $11.22 pivot point. If it approaches the $12.01 resistance level, significant changes may occur.

Previous Close:

$11.35

Open:

$11.35

24h Volume:

481.49K

Market Cap:

$513.85M

Revenue:

Net Income/Loss:

$-108.30M

P/E Ratio:

-3.8544

EPS:

-3.16

Net Cash Flow:

$-97.15M

1W Performance:

+17.68%

1M Performance:

+6.84%

6M Performance:

+38.88%

1Y Performance:

+37.32%

1D Range:

$11.35

$12.52

52W Range:

$7.21

$16.88

KalVista Pharmaceuticals Inc Stock (KALV) Company Profile

Name

KalVista Pharmaceuticals Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

857-999-0075

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA

Employee

Twitter

@kalvista

Next Earnings Date

2024-03-11

Latest SEC Filings

KALV's Discussions on Twitter

KalVista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-15-20	Initiated	H.C. Wainwright	Buy
Jul-29-19	Initiated	SVB Leerink	Outperform
Mar-20-19	Initiated	Needham	Buy
Oct-30-18	Initiated	Jefferies	Buy
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy

View All

KalVista Pharmaceuticals Inc Stock (KALV) Latest News

Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Benzinga

$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying

Benzinga

Insiders Buying Dorian LPG And 2 Other Stocks

Benzinga

KalVista Pharmaceuticals Inc Stock (KALV) Financials Data

KalVista Pharmaceuticals Inc (KALV) Net Income 2024

KALV net income (TTM) was -$108.30 million for the quarter ending January 31, 2024, a -19.38% decrease year-over-year.

KalVista Pharmaceuticals Inc (KALV) Cash Flow 2024

KALV recorded a free cash flow (TTM) of -$97.15 million for the quarter ending January 31, 2024, a -20.50% decrease year-over-year.

KalVista Pharmaceuticals Inc (KALV) Earnings per Share 2024

KALV earnings per share (TTM) was -$3.15 for the quarter ending January 31, 2024, a +11.76% growth year-over-year.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.